Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 6, 2007, Pages 540-548

  Hamilos, Daniel L ^a   D'Urzo, Anthony ^b   Levy, Robin J ^c   Marcus, Michael ^d   Tripp, Kenneth ^e   Parsey, Merdad ^e   Baumgartner, Rudolf A ^e   McVicar, William K ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Primary Care Lung Clinic   (Canada)

^c Family Allergy and Asthma Center   (United States)

^d Sepracor Inc ^*

^e SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVALBUTEROL; NORFLURANE; PIRBUTEROL; PLACEBO; SALBUTAMOL;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; OPEN STUDY; PAIN; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SINUSITIS; SPIROMETRY; STATISTICAL ANALYSIS; VIRUS INFECTION;

EID: 37349010357     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60384-5     Document Type: Article

References (44)

1. American Lung Association. Trends in asthma morbidity and mortality. 2006. Available at: www.lungusa.com. Accessed September 2, 2006.
2. Dey AN, Schiller JS, Tai DA. Summary health statistics for U.S. children: National Health Interview Survey, 2002. Vital Health Stat 10. 2004:1-78.
3. Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma-United States, 1960-1995. MMWR CDC Surveill Summ. 1998;47:1-27.
4. Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol. 1996;14:37-45.
5. Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem. 1971;14:895-899.
6. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. J Allergy Clin Immunol. 2005;116:65-72.
7. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther. 1998;11:1-6.
8. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol. 1994;7:367-376.
9. 2-agonists on ACH release and smooth muscle contraction in the trachea. Am J Physiol. 1998;274:L32-L38.
10. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol. 2001;124:478-484.
11. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol. 2002;109:449-454.
12. Yamaguchi H, McCullough JR. S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol. 1996;14:47-55.
13. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998;53:347-354.
14. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol. 2004;113:503-510.
15. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther. 1999;12:353-362.
16. Walle T, UK W, Thornburg K, Schey K. Stereoselective sulfation of albuterol in humans: biosynthesis of the sulfate conjugate by HEP G2 cells, drug metabolism and disposition. Br J Clin Pharmacol. 1992;21:76-80.
17. Schmekel B, Rydberg I, Norlander B, Sjosward KN, Ahlner J, Andersson RG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J. 1999;1230-1235.
18. Kraan J, Koeter GH, vd Mark TW, Sluiter HJ, de VK. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985;76:628-636.
19. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336:1391-1396.
20. 2-agonist treatment. Am Rev Respir Dis. 1993;148:707-712.
21. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging. 2004;21:405-414.
22. Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79:653-659.
23. Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis. 1988;138:850-855.
24. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993;342:833-837.
25. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol. 1995;96:44-49.
26. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997:1-153. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln. pdf. Accessed September 2, 2006.
27. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40-47.
28. Ramsdell JW, Klinger NM, Ekholm BP, Colice GL. Safety of long-term treatment with HFA albuterol. Chest. 1999;115:945-951.
29. US Department of Health and Human Services, FDA, CDER, CBER. Guidance for Industry E9 Statistical Principles for Clinical Trials. Washington, DC: US Dept of Health and Human Services; 1998.
30. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81-87.
31. Food and Drug Administration. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. Washington, DC: Food and Drug Administration; 1995:1-540.
32. Milgrom H, Skoner D, Bensch G, Kim K, Claus R, Baumgartner R. Low-dose levalbuterol in children with asthma: safety and efficacy compared with placebo and racemic albuterol. J Allergy Clin Immunol. 2001;108:938-945.
33. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102:943-952.
34. Maier G, Rubino C, Hsu R, Grasela T, Baumgartner RA. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. Pulm Pharmacol Ther. 2007;20:534-542.
35. Berger WE, Milgrom H, Skoner DP, Tripp K, Parsey MV, Baumgartner RA. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. Curr Med Res Opin. 2006;22:1217-1226.
36. Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol. 2005;40:477-486.
37. Dennis SM, Sharp SJ, Vickers MR, et al; Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet. 2000;355:1675-1679.
38. Beswick KB, Pover GM, Sampson S. Long-term regularly inhaled salbutamol. Curr Med Res Opin. 1986;10:228-234.
39. van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van WC, van Herwaarden CL. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990;86:793-800.
40. van Schayck CP, Dompeling E, van Herwaarden CL, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? a randomised controlled study. BMJ. 1991;303:1426-1431.
41. Taylor DR, Kennedy MA. Beta-adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics. 2002;3:173-184.
42. Weiss ST, Litonjua AA, Lange C, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. 2006;6:311-326.
43. Nelson HS. Clinical experience with levalbuterol. J Allergy Clin Immunol. 1999;104:S77-S84.
44. Asthma in America: A Landmark Survey. Washington, DC: Schulman, Ronca & Bucuvalas; 1998. Available at: www.asthmainamerica.com. Accessed September 2, 2006.